{"analyses":[{"ciLowerLimit":"0.224","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.633","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.377","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval not available due to high censoring.","groupId":"OG000","lowerLimit":"17.94","upperLimit":"NA","value":"24.18"},{"groupId":"OG001","lowerLimit":"9.66","upperLimit":"23.26","value":"11.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Participants censored: TRT A:74; TRT B: 25.","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months","title":"Duration of Response (DoR) by BICR (With Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}